For filings with the FCA include the annex |
|
||||
For filings with issuer exclude the annex |
|
||||
|
|||||
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi |
|||||
|
|
||||
1. Identity of the issuer or the underlying issuer |
Oxford Biomedica Plc |
||||
2 Reason for the notification (please tick the appropriate box or boxes): |
|||||
An acquisition or disposal of voting rights |
x |
||||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
|
||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
|
||||
An event changing the breakdown of voting rights |
|
||||
Other (please specify):
|
|
|
|||
3. Full name of person(s) subject to the |
Prudential plc group of companies |
||||
4. Full name of shareholder(s) |
Prudential plc M&G Group Limited M&G Limited M&G Investment Management Limited M&G Securities Limited
|
||||
5. Date of the transaction and date on |
25 February 2016 |
||||
6. Date on which issuer notified: |
29 February 2016 |
||||
7. Threshold(s) that is/are crossed or |
17% -18% |
||||
8. Notified details: |
|||||||||||||||||
A: Voting rights attached to shares viii, ix |
|||||||||||||||||
Class/type of
|
Situation previous |
Resulting situation after the triggering transaction |
|||||||||||||||
Number |
Number |
Number |
Number of voting |
% of voting rights x |
|||||||||||||
Direct |
Direct xi |
Indirect xii |
Direct |
Indirect |
|||||||||||||
ORD GBP0.01 GB0006648157 |
460,648,423 |
460,648,423 |
490,443,106 |
0 |
490,443,106 |
0 |
18.14% |
||||||||||
|
|||||||||||||||||
B: Qualifying Financial Instruments |
|||||||||||||||||
Resulting situation after the triggering transaction |
|||||||||||||||||
Type of financial |
Expiration |
Exercise/ |
Number of voting |
% of voting |
|||||||||||||
|
|
|
|
|
|||||||||||||
|
|||||||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi |
|||||||||||||||||
Resulting situation after the triggering transaction |
|||||||||||||||||
Type of financial |
Exercise price |
Expiration date xvii |
Exercise/ |
Number of voting rights instrument refers to
|
% of voting rights xix, xx
|
||||||||||||
|
|
|
|
|
Nominal |
Delta |
|||||||||||
|
|
||||||||||||||||
|
|||||||||||||||||
Total (A+B+C) |
|||||||||||||||||
Number of voting rights |
Percentage of voting rights |
||||||||||||||||
490,443,106 |
18.14% |
||||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or the |
||
Prudential plc (parent Company) - 490,443,106 (18.14%) M&G Group Limited (wholly owned subsidiary of Prudential plc) - 490,443,106 (18.14%) M&G Limited (wholly owned subsidiary of M&G Group Limited) - 490,443,106 (18.14%) M&G Investment Management Limited (wholly owned subsidiary of M&G Limited) - 490,443,106 (18.14%) M&G Securities Limited (wholly owned subsidiary of M&G Limited) - 466,658,885 (17.26%)
|
||
|
||
Proxy Voting: |
||
10. Name of the proxy holder: |
N/A |
|
11. Number of voting rights proxy holder will cease to hold: |
N/A |
|
12. Date on which proxy holder will cease to hold voting rights: |
N/A |
|
|
||
|
|
|
14. Contact name: |
Tim Watts |
|
15. Contact telephone number: |
Chief Financial Officer, Oxford BioMedica |
|